Global Rheumatoid Arthritis Drug Market and Ongoing Outlook 2022

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

Report Table of Contents

Antirheumatoids: Call of Rheumatoid Arthritis
1.1 Prologue towards Rheumatoid Arthritis
1.2 Obtainable Treatment for Rheumatoid Arthritis

Molecular Mechanism of Antirheumatoids
2.1 Purpose of DMARDs in Rheumatoid Arthritis
2.2 Role of Biological Agents in Rheumatoid Arthritis
2.2.1 TNF- Inhibitors
2.2.2 Interleukin -1 and IL-6 Blockers

Classification of Rheumatoid Arthritis Drugs
3.1 Traditional Classification of Rheumatoid Arthritis Drugs
3.2 New Proposed Classification of DMARDs

Synthetic DMARDs as Rheumatoid Arthritis Drug
4.1 Methotrexate (MTX)
4.2 Sulfasalazine (SSZ)
4.3 Leflunomide
4.4 Hydroxychloroquine (HCQ)

Biological Agents as Rheumatoid Arthritis Drug
5.1 Cytokine Inhibitors
5.1.1 Etanercept (Enbrel)
5.1.2 Infliximab (Remicade)
5.1.3 Adalimumab (Humira)
5.1.4 Golimumab (Simponi)
5.1.5 Certolizumab pegol (Cimzia)
5.2 Interleukin 1 and Interleukin 6 Inhibitors
5.2.1 Anakinra (Kineret)
5.2.2 Tocilizumab (RoActerma)
5.3 T-Cell and B-Cell Inhibitors
5.3.1 Abatacept (Orencia)
5.3.2 Rituximab (Mabthera)

Global Prevalence of Rheumatoid Arthritis
6.1 US
6.2 Europe
6.3 Canada
6.4 Asia

Global Tendencies in Use of Antirheumatics
7.1 Trail from Conventional to Biological DMARDs
7.2 Global Trends of Antirheumatic Prescription

Global Market of Rheumatoid Arthritis Drug
8.1 Market Overview of DMARDs
8.2 Market of Biosimilar DMARDs
8.3 Top Leading DMARDs by Revenues (2015 and 2022)
8.3.1 Humira (Adalimumab)
8.3.2 Enbrel (Etanercept)
8.3.3 Remicade
8.3.4 Simponi
8.3.5 Otezla (Celgene)

Global Rheumatoid Arthritis Drug Market Dynamics
9.1 Accelerative Parameters
9.2 Challenges

Global Rheumatoid Arthritis Drug Market Future Prospect

Competitive Landscape
11.1 Abbvie
11.2 Biogen Idec
11.3 Bristol-Myers Squibb
11.4 Celgene
11.5 Celltrion
11.6 JandJ
11.7 MedImmune
11.8 Merck
11.9 Novartis
11.10 Takeda

Figure 1-1: Representation of the Disease Progression in Rheumatoid Arthritis
Figure 2-1: Mechanism of Action of Anti-TNF in Rheumatoid Arthritis Treatment
Figure 3-1: Classified Antirheumatic Drugs Pattern in Course of Treatment
Figure 3-2: Demonstration of New Nomenclature for Antirheumatic Drugs
Figure 4-1: Structure of Several Synthetic Antirheumatic DMARDs
Figure 5-1: ACR Response Rate of Infliximab vs. Biosimilar CT-P13
Figure 5-2: Immunoglobulin Structures of the TNF Agonists including all Five Classes
Figure 6-1: Worldwide Prevalence of Rheumatoid Arthritis
Figure 6-2: Percentage of Rheumatoid Arthritis by Gender in US
Figure 6-3: Prevalence of Rheumatoid Arthritis over Ethnicity
Figure 6-4: Incidence of Rheumatoid Arthritis with Increasing Age
Figure 6-5: Illustration of Upcoming Risk of RA in US
Figure 6-6: Illustration of Percentage of Prevalence of Rheumatic Arthritis
Figure 6-7: Projected Number of Individuals with Rheumatism in Canada
Figure 7-1: Traditional Mode of Rheumatoid Arthritis Treatment
Figure 7-2: Illustration of Changes in Use of DMARDs after MTX
Figure 7-3: US: Percentage of Type of DMARDs Used for RA in 2013
Figure 8-1: Global - Rheumatoid Arthritis Drug Sales (US$ Billion), 2015-2022
Figure 8-2: Patent Expiration of Major Antirheumatic Drugs under Biologics in EU and US
Figure 8-3: Global - Top Rheumatoid Arthritis Drugs by Revenue from 2015 and 2022
Figure 8-4: Global andndash; Share of Top Rheumatoid Arthritis Drugs in Market (%),2022
Figure 8-5: Global - Humira Sales (US$ Billion), 2011-2015 and 2022
Figure 8-6: Global - Enbrel Sales (US$ Billion), 2015- 2016 and 2022
Figure 8-7: Global andndash; Remicade Sales (US$ Billion), 2015 and 2022
Figure 8-8: Global Percentage of Simponi Sale Revenues by Region (2015-2022) (Billions)
Figure 8-9: Global andndash; Simponi Sales (US$ Billion), 2015 and 2022
Figure 8-10: Global - Otezela Sales (US$ Billion) 2015 and 2022
Figure 9-1: Major Driving Forces of Antirheumatics Drug Market
Figure 9-2: Increasing Market Size of Biosimilars Worldwide
Figure 9-3: Major Challenges faced by Antirheumatics Market
Figure 9-4: Average Annual Treatment Cost of Humira, Enbrel and Remicade (US$), 2014
Figure 10-1: Global - Rheumatoid Arthritis Drug Market by Drug Class (TNF Inhibitors, JAK Inhibitors and Others) 2022

Download Report: https://www.kuickresearch.com/report-global-rheumatoid-arthritis-drug-market-outlook-2022.php

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.